Sonoma Pharmaceuticals, Inc. (SNOA) Earnings History
Annual and quarterly earnings data from 2005 to 2025
Loading earnings history...
SNOA EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
SNOA Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 38.2% | -26.0% | -24.2% |
| 2024 | 37.3% | -36.9% | -38.0% |
| 2023 | 33.7% | -34.4% | -38.8% |
| 2022 | 31.6% | -46.6% | -40.3% |
| 2021 | 35.2% | -18.5% | -21.2% |
Download Data
Export SNOA earnings history in CSV or JSON format
Free sign-in required to download data
Sonoma Pharmaceuticals, Inc. (SNOA) Earnings Overview
As of May 8, 2026, Sonoma Pharmaceuticals, Inc. (SNOA) reported trailing twelve-month net income of -$3M, reflecting +47.6% year-over-year growth. The company earned $-1.97 per diluted share over the past four quarters, with a net profit margin of -24.2%.
Looking at the long-term picture, SNOA's historical earnings data spans multiple years. The company achieved its highest annual net income of $9M in fiscal 2017.
Sonoma Pharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including SSKN (-$11M net income, -30.1% margin), DERM (-$9M net income, -26.1% margin), PRPH (-$42M net income, -788.2% margin), SNOA has outperformed on profitability metrics. Compare SNOA vs SSKN →
SNOA Earnings vs Peers
Earnings metrics vs comparable public companies
SNOA Historical Earnings Data (2005–2025)
21 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$3M | +28.5% | -$4M | $-2.79 | -24.2% | -26.0% |
| 2024 | -$5M | +6.1% | -$5M | $-5.32 | -38.0% | -36.9% |
| 2023 | -$5M | -1.3% | -$5M | $-15.18 | -38.8% | -34.4% |
| 2022 | -$5M | -28.8% | -$6M | $-19.17 | -40.3% | -46.6% |
| 2021 | -$4M | -19.4% | -$3M | $-23.65 | -21.2% | -18.5% |
| 2020 | -$3M | +72.0% | -$7M | $-22.40 | -18.5% | -41.2% |
| 2019 | -$12M | +17.7% | -$11M | $-127.68 | -62.2% | -59.3% |
| 2018 | -$14M | -254.5% | -$14M | $-284.66 | -86.0% | -85.2% |
| 2017 | $9M | +191.3% | -$13M | $-221.70 | 72.3% | -101.2% |
| 2016 | -$10M | -23.9% | -$15M | $-117.81 | -108.5% | -157.0% |
See SNOA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SNOA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SNOA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSNOA — Frequently Asked Questions
Quick answers to the most common questions about buying SNOA stock.
Is SNOA growing earnings?
SNOA EPS is $-1.97, with earnings growth accelerating to +47.6%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-3M.
What are SNOA's profit margins?
Sonoma Pharmaceuticals, Inc. net margin is -24.2%, with operating margin at -26.0%. Below-average margins reflect competitive or cost pressures.
How consistent are SNOA's earnings?
SNOA earnings data spans 2005-2025. The accelerating earnings trend is +47.6% YoY. Historical data enables comparison across business cycles.